NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
Oklahoma reports declines in adult and childhood obesity, citing state initiatives and community programs for healthier lifestyles.
At the heart of this epidemic lies insulin resistance, a metabolic dysfunction that Karan Sarin calls the common denominator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback